Result of GM and Total Voting Rights
Futura Medical plc announced that all resolutions presented at its General Meeting on September 23, 2026, were passed, with significant support for each, including over 96.99% of votes cast for resolutions concerning the proposed placing, subscription, and retail offer. The company has applied for the admission of 23,500,000 Subscription Shares, 719,367,225 Conditional Placing Shares, and 100,000,000 Retail Offer Shares to AIM, with trading expected to commence around September 25, 2026. Following admission, Futura Medical will have 1,482,327,755 ordinary shares in issue, representing the total voting rights.
Select text to share a quote on X · sign in to keep highlights & notes in your FUM notes
The following amendment has been made to the 'Result of General Meeting and Total Voting Rights' announcement released on 24/09/26 at 10:36 under RNS No 1721.
The amendment relates to the Retail Offer Shares figure, which should read 100,000,000. All other details remain unchanged.
The full amended text is shown below.
Futura Medical plc
("Futura", "the Company" or “the Group”)
Result of General Meeting and Total Voting Rights
Futura Medical (AIM:FUM), the consumer healthcare group behind Eroxon®, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, announces that following the General Meeting held on 23 September 2026 at the offices of Panmure Liberum, 25 Ropemaker Street, London EC2Y 9LY at 10:00 a.m., all resolutions set out in the notice of General Meeting contained in the Circular dated 4 September 2026 were duly passed.
Resolutions 1 and 3 were proposed as ordinary resolutions and resolutions 2, 4 and 5 were proposed as special resolutions. The total number of votes received on each resolution were as follows:
| For | Against | |||||
|---|---|---|---|---|---|---|
| Resolution | Votes For | % of votes cast | Votes Against | % of votes cast | Votes withheld | Total votes cast |
| 1 | 86,354,516 | 97.05 | 2,629,309 | 2.95 | 747,805 | 88,983,825 |
| 2 | 86,289,880 | 97.00 | 2,667,548 | 3.00 | 774,202 | 88,957,428 |
| 3 | 86,291,292 | 97.09 | 2,585,822 | 2.91 | 854,516 | 88,877,114 |
| 4 | 86,334,169 | 96.99 | 2,677,612 | 3.01 | 719,849 | 89,011,781 |
| 5 | 86,343,483 | 96.99 | 2,675,631 | 3.01 | 712,516 | 89,019,114 |
Accordingly, all conditions precedent relating to the proposed placing, subscription and retail offer (the “Fundraise”) announced on 3 September 2026 have now been met (save for Subsequent Admission).
Application has been made for 23,500,000 Subscription Shares, 719,367,225 Conditional Placing Shares and 100,000,000 Retail Offer Shares to be admitted to trading on AIM, it is expected that the admission will become effective and that dealings will commence at 8.00 a.m. on or around 25 September 2026.
Total Voting Rights
Following the Admission, the Company will have 1,482,327,755 ordinary shares of £0.002 each in issue.
The Company does not hold any shares in treasury and all of the Ordinary Shares have equal voting rights. Therefore, the figures above represent the total voting rights in the Company and this figure may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the voting rights of the Company under the FCA's Disclosure Guidance and Transparency Rules
Unless otherwise stated, capitalised terms not otherwise defined in the text of this announcement have the same meanings ascribed to them as in the announcement released by the Company on 3 September 2026.
- ENDS –
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.